---
document_datetime: 2024-03-20 15:07:13
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zeffix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zeffix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 14.704487
conversion_datetime: 2025-12-26 12:06:10.453404
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zeffix

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0088              | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 15/03/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0087   | Update of section 4.4 of the SmPC in order to amend an existing warning on HIV/HBV co-infection, particularly regarding the importance of HIV testing and the risk of HIV resistance with subtherapeutic doses of lamivudine and/or monotherapy in patients with HIV/HBV co-infection. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 15/02/2024   |     | SmPC and PL   | The following update of section 4.4 of the SmPC was considered to further contribute to the adequate management of patients co-infected with hepatitis B virus (HBV) and HIV: The 100 mg usual dose of lamivudine used for the treatment of HBV is not appropriate for patients who acquire HIV or are co infected with HBV and HIV. If a patient with unrecognised or untreated HIV infection is prescribed the dose of lamivudine recommended for the treatment of HBV, rapid emergence of HIV resistance and a limitation of treatment options is likely to result because of the subtherapeutic dose and the inappropriate use of monotherapy for HIV treatment. HIV counselling and testing should be offered to all patients before beginning treatment with lamivudine for HBV and periodically during treatment.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0086/G | This was an application for a group of variations. B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                | 25/10/2023   | n/a |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0085/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                              | 20/10/2023   | n/a |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                              |            |            |                 |                                                                                                                                                                                                                                          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0084 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                  | 18/07/2022 | 17/07/2023 | Annex II and PL |                                                                                                                                                                                                                                          |
| II/0083   | Update of sections 4.9 of the SmPC in order to update the Overdosage of the GDS for lamivudine- human immunodeficiency virus (HIV) information based on the safety database. The section 3 of the package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/09/2021 | 18/11/2021 | SmPC and PL     | Based on safety database, the overdose symptoms and signs text of the SmPC has been updated. Accordingly the package leaflet has been updated as well. For more information, please refer to the Summary of Product Characteristics.     |
| II/0082   | Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on results from bioavailability studies (204993 and 204994) with lamivudine-containing products. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                   | 23/09/2021 | 18/11/2021 | SmPC            | Based on observed results from bioavailability studies with lamivudine-containing products, the lamivudine elimination half-life values have been updated. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| N/0081             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                | 20/09/2021   | 18/11/2021   | PL              |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|-----------------------------------|
| PSUSA/1824/ 202007 | Periodic Safety Update EU Single assessment - lamivudine (chronic hepatitis B)                                                                                                                                                                                                                                                                                                                                                                  | 11/03/2021   | n/a          |                 | PRAC Recommendation - maintenance |
| IAIN/0080/G        | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 25/01/2021   | 18/11/2021   | Annex II and PL |                                   |
| IAIN/0079/G        | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.7 - Administrative change - Deletion of manufacturing sites                                                                                         | 25/01/2021   | 18/11/2021   | Annex II and PL |                                   |
| IA/0078            | A.5.b - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                              | 08/01/2021   | n/a          |                 |                                   |

<div style=\"page-break-after: always\"></div>

|           | address of a manufacturer/importer of the product, including quality control sites manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                       |            |            |                                  | and/or finished (excluding   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------|
| IB/0076   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                           | 28/10/2020 | 18/11/2021 | SmPC, Annex II, Labelling and PL |                              |
| IA/0075   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                            | 08/11/2019 | 11/02/2020 | Annex II and PL                  |                              |
| IAIN/0074 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                   | 15/02/2019 | 11/02/2020 | Annex II and PL                  |                              |
| T/0073    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/10/2018 | 26/11/2018 | SmPC, Labelling and PL           |                              |
|           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 25/05/2018 | n/a        |                                  | IA/0072/G intermediate used  |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0069   | Update of section 4.5 of the SmPC to add information regarding the interaction between lamivudine and sorbitol-containing medicines based on the results of Study 204857. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement a minor change in the labelling in line with the QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                    | 25/01/2018 | 26/11/2018 | SmPC, Labelling and PL | Study 204857 was undertaken to evaluate the effect of sorbitol on the pharmacokinetics of lamivudine. The study concluded that concomitant use of lamivudine with chronic administration of sorbitol containing medicines may reduce the exposure of lamivudine, possibly resulting in reduced virologic suppression or viral resistance. Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. When possible, avoid chronic co-administration of Zeffix with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HBV viral load when chronic co- administration cannot be avoided. |
| IB/0071/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters | 11/01/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0070            | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                              | 27/04/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0068            | Update of sections 4.4 and 4.6 of the SmPC to reflect pregnancy clinical outcome data from the Antiretroviral Pregnancy Registry (APR). In addition, an introductory paragraph for pregnancy has been added to section 4.6 of the SmPC in line with Epivir (lamivudine for Human Immunodeficiency Virus Indication) (variation II/84). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 02/02/2017 | 22/05/2017 | SmPC                             | There is limited information available on maternal-foetal transmission of hepatitis B virus in pregnant women receiving treatment with lamivudine. Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats. Placental transfer of lamivudine has been shown to occur in humans. Available human data from the Antiretroviral Pregnancy Registry reporting more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure in pregnant women indicate no malformative and foeto/neonatal effect. Less than 1% of these women have been treated for HBV, whereas the majority was treated for HIV at higher doses and with other concomitant medications. Zeffix can be used during pregnancy if clinically needed. For patients who are being treated with lamivudine and subsequently become pregnant consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine. |
| IB/0067            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                           | 24/06/2016 | 22/05/2017 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/1824/ 201507 | Periodic Safety Update EU Single assessment - lamivudine (chronic hepatitis B)                                                                                                                                                                                                                                                                                                                                                                           | 01/04/2016 | 26/05/2016 | SmPC, Annex II, Labelling and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1824/201507.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| IAIN/0066/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                       | 21/12/2015   | 26/05/2016   | Annex II and PL   |                      |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|----------------------|
| IA/0064       | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                         | 08/05/2015   | n/a          |                   |                      |
| IB/0063/G     | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation change - Change in the name | 08/08/2014   | n/a          |                   | A.4 - Administrative |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or address of a manufacturer or supplier of the AS, starting intermediate used in the manufacturer of a novel A.7 - Administrative change manufacturing sites B.I.a.2.a - Changes in the the AS - Minor change of the AS B.I.a.2.a - Changes in the the AS - Minor change of the AS B.I.a.2.a - Changes in the the AS - Minor change of the AS B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.a.3.a - Change in batch ranges) of AS or intermediate increase compared to the size B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, material/intermediate/reagent B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| and/or limits of an AS, material/intermediate/reagent B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation           |            |            |                                  |                                                                                                                                                                                                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0062    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                | 25/04/2014 | 23/06/2014 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the risk-benefit balance of Zeffix remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| N/0061    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                       | 04/10/2013 | 10/01/2014 | SmPC and PL                      |                                                                                                                                                                                                                                           |
| IB/0055/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size | 12/06/2013 | n/a        |                                  |                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IA/0060   | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 06/06/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0058   | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/04/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0059 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 19/04/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IG/0279   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 18/04/2013   | 10/01/2014 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0056   | B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                                                                                                                                                         | 15/04/2013   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0053   | The MAH proposed the update of sections 4.5 and 4.4. of the SPC, following the changes requested by CHMP AR of November 2011 concerning FUM 050.2 to specify that concomitant use of lamivudine and cladribine is not recommended. The package Leaflet is updated in accordance. Furthermore the MAH took this opportunity to make other updates required for full compliance with QRD template. Minor updates to the local representative contact information in Belgium, Czech Republic, Cyprus, Poland and Luxembourg were also introduced. The requested variation proposed amendments to | 17/01/2013   | 20/12/2013 | SmPC, Annex II, Labelling and PL | In the last PSUR a literature article (Chtioui et al 2008 Brit J Haematol 144: 131-142) relating a possible interaction between cladribine and lamivudine was provided. A patient with chronic lymphocytic leukaemia (CLL) receiving lamivudine showed no effect from cladribine until lamivudine was discontinued. The authors suspected a potential interaction based on intracellular phosphorylation of the two medicines and an in vitro study was carried out using peripheral blood mononuclear cells isolated from a healthy volunteer. This in vitro study showed that phosphorylated cladribine levels were decreased with increasing lamivudine concentrations, in line with what expected as per cladribine Product |

<div style=\"page-break-after: always\"></div>

|           | the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet. C.I.3.z - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Other variation                                                                                                                                                                         |            |            |                 | Information. While the robustness of the findings and their clinical relevance remain unclear (this concomitant use in clinical practice is likely to be very rare, a literature research only retrieved this single case report, and no other haematological parameters as red blood cells or platelets count were evaluated) the potential for this drug interaction supported by the in vitro study justifies updating the Product Information.                                                              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0052    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                       | 14/12/2012 | 20/12/2013 | PL              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0051 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                      | 24/11/2011 | 27/06/2012 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0050   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                    | 26/04/2011 | n/a        | SmPC            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0049   | IIn fulfilment of FUM 044.1, section 4.4 of the SmPC has been amended to improve clarity around the current text on exacerbation of hepatitis, in line with other nucleoside agents for CHB, and section 4.8 has been updated with regards to the frequency category of ADR based on the SmPC Guideline rev. 2. The PL has been revised accordingly. The MAH took this opportunity to amend the contact details of the Danish representative in the PL, to implement a | 21/10/2010 | 26/11/2010 | SmPC and PL     | Section 4.4 of the SmPC has been amended to improve clarity around the text on exacerbation of hepatitis, in line with other nucleoside agents for CHB. The approved text i) differentiate information related to development of resistance and post-treatment exacerbations of ALT flares, ii) better reflects data on post-treatment ALT elevations. Section 4.8 has been updated with regards to the frequency category of ADR based on the rule of 3/X recommended in the latest SmPC Guideline. The PL has |

<div style=\"page-break-after: always\"></div>

|         | of variation II-47 and to align SmPC and PL to the latest QRD template. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                     |            |            |                                  | been modified accordingly.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------|
| II/0047 | To update sections 4.2, 4.4, 4.6 and 5.1 of the SPC as a response to the commitments made by the MAH as part of the Zeffix licence renewal. The PL was revised accordingly. The MAH took the opportunity of this variation to update the contact details for the Danish, German and Cypriot local representatives and to introduce minor changes in the PL. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 20/05/2010 | 02/07/2010 | SmPC, Annex II and PL            |                              |
| R/0046  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                 | 29/05/2009 | 27/08/2009 | SmPC, Annex II, Labelling and PL |                              |
| II/0045 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                         | 24/01/2008 | 28/01/2008 |                                  |                              |
| IA/0044 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                    | 18/12/2007 | n/a        | Annex II and PL                  |                              |
| IA/0043 | IA_05_Change in the name and/or address of a                                                                                                                                                                                                                                                                                                                                                                                            | 18/12/2007 | n/a        | Annex II and                     |                              |

<div style=\"page-break-after: always\"></div>

|         | manufacturer of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0040 | To update sections 4.2 and 5.1 of the SPC to increase the continuation of therapy from HbeAg seroconversion from 3 months to at least 3-6 months and to include a wording relating to the rate of late virological relapses, as requested by the CHMP in August 2006. This follows the assessment of an epidemiological clinical study over five years in patents with or without YMDD mutants together with a comparative literature review. Update of Summary of Product Characteristics | 24/01/2007 | 27/02/2007 | SmPC | A 5-year open off-treatment epidemiologic study was performed to provide data on the durability of post- treatment responses. The final results of this study show that late virological relapses occur in 39% of HBeAg+ve patients who seroconverted post lamivudine treatment. These results together with data from a comprehensive literature review performed by the MAH indicate that the HBeAg seroconversion is not sufficient to ensure that a sustained response could be obtained and section 5.1 of the SPC was revised to include this information. Furthermore, according to data from a literature review and in line with the current international treatment guidelines, section 4.2 of the SPC was amended to allow continuation of treatment with Zeffix for at least 3-6 months from HBeAg seroconversion instead of the currently recommended duration of 3 months. |
| IA/0042 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                         | 20/02/2007 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0041 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                   | 13/11/2006 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0038 | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/08/2006 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0039 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                                                                                                                                                                                                           | 26/07/2006 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0037   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/07/2006   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035   | To update section 4.4 and 4.8 of the SPC of Zeffix tablets and oral solution to re-organise information on exacerbation of hepatitis as requested by CHMP following the evaluation of PSUR 17 covering the period from 1 August 2004 to 31 July 2005. Additionally the MAH proposed to update section 4.8 of the SPC to introduce rhabdomyolysis as a very rare side effect. The PL was updated accordingly. Furthermore, the MAH updated the product information according to QRD v07. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 01/06/2006   | 04/07/2006 | SmPC, Annex II, Labelling and PL | Exacerbations of hepatitis During the year covered by PSUR n. 17 (from 1 August 2004 to 31 July 2005), four fatal cases with hepatic events occurring after lamivudine withdrawal were recorded. Severe post-treatment flares, which can be fatal are recognised to occur following withdrawal of lamivudine and such events are currently described in section 4.4 \"Special warnings and precautions for use\" of the SPC. Given the importance of this information, the CHMP concluded that section 4.4 of the SPC should be re-organized so as to have a sub-title \"exacerbation of hepatitis\" reflecting the possibility of per-treatment and post-treatment exacerbation of hepatitis whether or not associated with viral resistance. Furthermore, such serious adverse events so far not listed in section 4.8 \"Undesirable effects\" of the SPC have been added. Rhabdomyolysis Following the assessment of PSUR n. 17, and given the medical seriousness of rhabdomyolysis (can induce serious and life threatening renal damage), a cumulative review of available data was considered warranted and was provided by the MAH. Therefore, rhabdomyolysis has been added as a very rare adverse reaction in section 4.8 under the heading of \"Musculoskeletal and connective tissue disorders\" of the SPC. |
| IA/0036   | IA_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 30/03/2006   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IA/0034   | IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                             | 21/03/2006   | n/a        | Annex II and PL                  |                         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------|
| IA/0033   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site - Solid forms | 21/03/2006   | n/a        |                                  | site: Primary packaging |
| IB/0031   | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                             | 15/02/2006   | n/a        |                                  |                         |
| IB/0030   | IB_14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                        | 15/02/2006   | n/a        |                                  |                         |
| IA/0032   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                         | 18/01/2006   | n/a        |                                  |                         |
| II/0029   | Update of Summary of Product Characteristics                                                                                             | 16/03/2005   | 25/04/2005 | SmPC                             |                         |
| II/0028   | Update of Summary of Product Characteristics                                                                                             | 16/03/2005   | 25/04/2005 | SmPC                             |                         |
| II/0027   | Update of Summary of Product Characteristics                                                                                             | 17/02/2005   | 29/03/2005 | SmPC                             |                         |
| R/0024    | Renewal of the marketing authorisation.                                                                                                  | 29/07/2004   | 20/10/2004 | SmPC, Annex II, Labelling and PL |                         |
| IA/0026   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                         | 03/09/2004   | n/a        |                                  |                         |
| N/0025    | To update the list of local representatives in the Package Leaflet (PL) , to include the local                                           | 25/06/2004   | n/a        | PL                               |                         |

<div style=\"page-break-after: always\"></div>

|         | of the ten new European Member and to update the format of the PL according the latest EMEA/QRD template. change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             | representatives States to Minor connected   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------|
| IA/0023 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 01/03/2004 | n/a        |             |                                             |
| IB/0022 | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/02/2004 | n/a        |             |                                             |
| II/0015 | To update the Summary of Product Characteristics (SPC) further to the CPMP assessment of the PSUR covering 1 June - 30 November 2002. This includes reformatting section 4.8 \"Undesirable effects\" presenting the adverse drug reactions by MedDRA system organ class and ranked by frequency and the inclusion of the adverse reactions thrombocytopenia and muscle disorders, including myalgia and cramps. Furthermore, the SPC has been updated in line with the latest EMEA/QRD templates. The package Leaflet (PL) has been updated accordingly. Furthermore, the name of manufacturer has been corrected in the Danish PL. Update of Summary of Product Characteristics and Package Leaflet | 22/10/2003 | 20/01/2004 | SmPC and PL |                                             |

<div style=\"page-break-after: always\"></div>

|         | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                           | 29/10/2003   | n/a        |                        | I/0016   |
|---------|------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------|
| I/0014  | 24_Change in test procedure of active substance                                                      | 05/08/2003   | 19/08/2003 |                        |          |
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 15/01/2003   | 17/02/2003 | Labelling and PL       |          |
| II/0006 | Update of Summary of Product Characteristics                                                         | 19/09/2002   | 19/12/2002 | SmPC                   |          |
| I/0008  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process       | 30/07/2002   | 09/09/2002 | Annex II and PL        |          |
| I/0011  | 16_Change in the batch size of finished product                                                      | 30/07/2002   | n/a        |                        |          |
| I/0010  | 15_Minor changes in manufacture of the medicinal product                                             | 30/07/2002   | n/a        |                        |          |
| I/0009  | 08_Change in the qualitative composition of immediate packaging material                             | 30/07/2002   | n/a        |                        |          |
| I/0007  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process       | 30/07/2002   | n/a        |                        |          |
| I/0005  | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance | 08/05/2002   | 17/05/2002 |                        |          |
| II/0004 | Update of Summary of Product Characteristics and Package Leaflet                                     | 13/12/2001   | 02/04/2002 | SmPC, Labelling and PL |          |

<div style=\"page-break-after: always\"></div>

| II/0002   | Update of Summary of Product Characteristics and Leaflet   | 14/12/2000   | 23/04/2001   | SmPC,         |
|-----------|------------------------------------------------------------|--------------|--------------|---------------|
|           | Package                                                    |              |              | Labelling and |
|           |                                                            |              |              | PL            |